HOUSTON, TX / ACCESSWIRE / October 16, 2023 / Glioblastoma is the most aggressive type of brain cancer, with an average survival of only 14 to 16 months after diagnosis. There is currently no cure for glioblastoma, and it is a highly invasive tumor that makes complete surgical removal difficult. Even with aggressive treatment, the cancer tends to recur, leading to a grim prognosis.

德克萨斯州休斯顿/ACCESSWIRE/2023年10月16日/胶质母细胞瘤是最具侵袭性的脑癌类型，诊断后平均存活时间仅为14至16个月。目前还没有治愈胶质母细胞瘤的方法，它是一种高度侵袭性的肿瘤，难以完全手术切除。即使采取积极治疗，癌症也会复发，导致预后严峻。

The high mortality rate of glioblastoma is also due to its resistance to chemotherapy and radiation treatments, which can damage healthy brain tissue. Glioblastoma affects 12,000 to 15,000 people in the U.S. each year..

胶质母细胞瘤的高死亡率也是由于其对化学疗法和放射疗法的抗性，这可能损害健康的脑组织。胶质母细胞瘤每年影响美国12000至15000人。。

There is currently a high unmet need for effective treatments for glioblastoma. While there are some therapies available, such as surgery, chemotherapy and radiation, they do not appear to be very effective in prolonging survival. In recent years, there has been a growing interest in immunotherapy and precision medicine, with researchers working to develop treatments that can more effectively target the specific genetic mutations and molecular pathways involved in glioblastoma growth.

目前对胶质母细胞瘤有效治疗的需求尚未得到满足。虽然有一些治疗方法可用，如手术，化疗和放疗，但它们似乎对延长生存期不是很有效。近年来，人们对免疫疗法和精准医学越来越感兴趣，研究人员致力于开发能够更有效地靶向涉及胶质母细胞瘤生长的特定基因突变和分子途径的治疗方法。

However, success in these efforts has been limited..

但是，这些努力的成功是有限的。。

One biopharmaceutical company to note in the space is CNS Pharmaceuticals (NASDAQ:CNSP), which is focused on developing innovative therapies to treat diseases of the central nervous system (CNS). Their mission is to address critical unmet needs in CNS disorders - particularly aggressive brain cancers, including glioblastoma - by developing effective and targeted treatments..

在太空中要注意的一家生物制药公司是CNS制药公司（纳斯达克股票代码：CNSP），该公司专注于开发治疗中枢神经系统疾病（CNS）的创新疗法。他们的使命是通过开发有效和有针对性的治疗方法来解决中枢神经系统疾病（尤其是侵袭性脑癌，包括胶质母细胞瘤）中至关重要的未满足需求。。

CNS Pharmaceuticals' lead product candidate, Berubicin, is a chemotherapy drug being investigated for the treatment of glioblastoma. Bereubicin is an anthracycline, a class of chemotherapy drugs that has as a whole a history of more than sixty years of safe and effective clinical use in the treatment of a variety of cancers.

CNS Pharmaceuticals的主要候选产品Berubicin是一种正在研究用于治疗胶质母细胞瘤的化疗药物。Bereubicin是一种蒽环类药物，是一类化疗药物，在治疗各种癌症方面具有六十多年安全有效的临床应用历史。

The innovation of Berubicin lies in its ability to overcome challenges specific to CNS tumor treatment. Traditionally, chemotherapy drugs struggle to reach the tumor cells in the brain due to the blood-brain barrier. Berubicin was specifically designed to solve this problem, and CNS Pharmaceuticals reports that it has demonstrated Berubicin's ability to penetrate this barrier, enabling it to directly target cancer cells in the brain, an ability shared by very few chemotherapy drugs.

柔红霉素的创新在于其克服CNS肿瘤治疗特有挑战的能力。传统上，由于血脑屏障，化疗药物难以到达大脑中的肿瘤细胞。Berubicin是专门为解决这个问题而设计的，CNS制药公司报告说，它已经证明了Berubicin能够穿透这种屏障，使其能够直接靶向大脑中的癌细胞，这是极少数化疗药物共有的能力。

This breakthrough feature enables the potential effectiveness of the treatment..

这一突破性特征使治疗的潜在有效性成为可能。。

Berubicin is further distinct in that it works by interfering with the replication of DNA in cancer cells, which prevents them from dividing and growing. By penetrating the blood-brain barrier and directly targeting the cancer cells, Berubicin aims to inhibit their growth and potentially shrink tumors..

Berubicin的进一步区别在于它通过干扰癌细胞中DNA的复制而起作用，这阻止了它们的分裂和生长。通过穿透血脑屏障并直接靶向癌细胞，Berubicin旨在抑制其生长并可能缩小肿瘤。。

CNS Pharmaceuticals has received FDA Orphan Drug Designation, which grants them seven years of exclusive marketing rights upon a New Drug Application approval. They have also been granted Fast Track Designation, enabling increased interaction with the FDA to expedite the development and review of drugs for serious or life-threatening conditions with unmet medical needs.

CNS Pharmaceuticals已获得FDA孤儿药名称，该名称在新药申请批准后授予他们七年的独家营销权。他们还获得了快速通道认证，可以加强与FDA的互动，加快药物的开发和审查，以满足未满足医疗需求的严重或危及生命的疾病。

To expand the company's international footprint, CNS Pharmaceuticals intends to pursue Orphan status in Europe and Japan, which would offer 10 years of market exclusivity in those territories if granted..

为了扩大公司的国际足迹，CNS制药公司打算在欧洲和日本寻求孤儿地位，如果获得批准，将在这些地区提供10年的市场独占权。。

CNS Pharmaceuticals is actively conducting a potentially pivotal phase 2 clinical trial to evaluate the safety and effectiveness of Berubicin, with over 229 patients currently enrolled. This trial aims to assess the drug's ability to improve outcomes for patients with glioblastoma. The phase 1 study of Berubicin showed that 44% of the patients experienced a clinical benefit of stable disease or better, with one Durable Complete Response (a demonstrated lack of detectable cancer cells).

CNS Pharmaceuticals正在积极开展一项潜在的关键性2期临床试验，以评估柔红霉素的安全性和有效性，目前有229多名患者入选。该试验旨在评估该药物改善胶质母细胞瘤患者预后的能力。Berubicin的1期研究显示，44%的患者经历了稳定疾病或更好的临床益处，具有持久的完全反应（证明缺乏可检测的癌细胞）。

The company's dedication to developing novel therapies for CNS disorders, along with the unique mechanism and innovative delivery of Berubicin, offers hope for improved treatment options and outcomes for patients battling aggressive brain cancers..

该公司致力于开发新的中枢神经系统疾病治疗方法，以及独特的机制和创新的柔红霉素输送，为改善与侵袭性脑癌作斗争的患者的治疗选择和结果提供了希望。。

Featured photo by National Cancer Institute on Unsplash.

国家癌症研究所在UNFLASH上的特色照片。

Contact:

联系方式：

Justin Romanowski

贾斯汀·罗曼诺夫斯基

justin@jtcir.com

justin@jtcir.com

SOURCE: CNS Pharmaceuticals, Inc.

来源：CNS制药公司。

View source version on accesswire.com:

在AccessWire.com上查看源版本：

https://www.accesswire.com/793322/glioblastoma-is-the-most-aggressive-type-of-brain-cancer-with-no-cure--cns-pharmaceuticals-innovative-approach-to-treatment-could-offer-hope

https://www.accesswire.com/793322/glioblastoma-is-the-most-aggressive-type-of-brain-cancer-with-no-cure--cns-pharmaceuticals-innovative-approach-to-treatment-could-offer-hope